Translational Medicine Department Strengthens Research & Development Team
CLINTON, N.J., June 24 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced that Michael Cooreman, M.D., has been introduced as Vice President of Translational Medicine, reporting to Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria.
As Vice President of Translational Medicine, Dr. Cooreman is responsible for leading the Company's Translational Medicine Department. Translational Medicine seeks to define as early as possible the indications for which a new compound will most likely show therapeutic benefit, based on the known interaction of the compound in disease pathways, in addition to confirmation of safety and efficacy of that compound in animal studies. Once likely indications are determined, a clinical proof-of-concept study is initiated with the goal of demonstrating clinical safety, pharmacokinetic properties and therapeutic efficacy study in a particular disease. The results are used to make a data-based decision on whether or not to initiate a Phase 3 trial.
Dr. Rosskamp commented, "In this recently created position, Michael will help us translate pre-clinical research findings into meaningful, early clinical trials. Translational Medicine is often defined as 'bench-to-bedside' research and represents a paradigm shift of developing new drugs and devices. Rather than progressing a new drug or device from preclinical research through traditional Phase 1 to 3 development, we will now focus on a much earlier patient-oriented research. This will help Ikaria to accelerate our decision-making process on promising compounds and indications, which we believe will increase our success rate once we enter the costly late stage development phase."
Daniel Tasse, President & CEO of Ikaria, remarked, "Translational
Medicine incorporates the use of tools such as biomarkers to bette
|SOURCE Ikaria Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved